Cellestia Biotech receives investment to advance first-in-class therapies to control and modulate pathogenic gene expression
SNGLR Capital AG, based in Zug, Switzerland, announces its first investment in Basel-based biotech company Cellestia Biotech. Cellestia was a Venture Leader China in 2018 and one of the TOP 100 Swiss Startups from 2016 to 2019.
SNGLR Capital AG, with its early-stage exponential technology venture capital fund, is very glad to join a great shareholder community and is pleased to support Cellestia on its further development.
“Our investment thesis focuses, among other things, on applications in the field of personal medicine with strong growth potential. We see these points very well supported by Cellestia. Above all, the advanced phase II study data allow an investment with less risk compared to other early-stage investment rounds,”
said Dr. med Eszter Tanzcos Olver, Lead Partner Longevity SNGLR Capital.
“We were very impressed by the promising Phase I data with sign of clinical efficacy of the CB-103, a first-in-class small molecule targeted therapy with a novel mode of action and the efficiency of the Cellestia team. It is very exciting to contribute with our investment, to help many people who today have no treatment option with this new therapy tailored to the oncology profile of an individual patient,”
said Klaus Kummermehr, CEO of SNGLR Capital.
“It is a great honor for us to welcome SNGLR Capital as new institutional investor, and we thank for the investment in our company. The additional capital will enable us to reach important milestones and to continue creating value for our shareholders,”
said Gaudenz von Capeller, CFO of Cellestia Biotech AG.
Cellestia was a Venture Leader China
in 2018 and one of the TOP 100 Swiss Startups
from 2016 to 2019.
Read the original news on: www.venturelab.swiss